Early Weight Loss Within 20 Weeks Predicts Lasting Relief From Sleep Apnoea

For the roughly one billion people worldwide living with obstructive sleep apnoea, a new analysis of landmark clinical trial data offers a strikingly simple message: how much weight you lose in the first five months of treatment may determine whether the disorder ever truly loosens its grip. In a post hoc analysis of the SURMOUNT-OSA trials published in eClinicalMedicine, researchers found that participants with moderate-to-severe obstructive sleep apnoea and obesity who shed at least 10 percent of their body weight by week 20 experienced dramatically greater and more durable improvements in breathing during sleep than those who lost less, regardless of whether they were also using positive airway pressure machines.

Obstructive sleep apnoea is far more than loud snoring. The disorder involves repeated collapse of the upper airway during sleep, cutting off airflow dozens or even hundreds of times per night. Each episode starves the body of oxygen, fragments sleep, and triggers surges of stress hormones. The consequences accumulate silently: untreated apnoea is linked to hypertension, myocardial infarction, stroke, and increased all-cause mortality. More than 425 million adults aged 30 to 69 are estimated to have the moderate-to-severe form of the disease, making it one of the largest underrecognised burdens in modern medicine.

Obesity sits at the centre of this epidemic. Excess fat deposited around the upper airway increases the throat’s tendency to collapse, while visceral abdominal fat impairs ventilatory control, reduces lung volumes, and diminishes the traction that normally helps hold the airway open. More than 60 percent of moderate-to-severe sleep apnoea cases are attributable to obesity, and disease severity tracks closely with body mass index. Weight reduction has long been a cornerstone of non-drug management, but until now clinicians have lacked answers to two crucial questions: how fast must the weight come off, and how much is enough to change the disease trajectory?

The new study drew on the SURMOUNT-OSA programme, two 52-week, randomised, double-blind, placebo-controlled phase 3 trials that tested tirzepatide, a dual GIP and GLP-1 receptor agonist already approved by the United States Food and Drug Administration for treating moderate-to-severe sleep apnoea in adults with obesity. Trial 1 enrolled participants not using positive airway pressure therapy, while trial 2 enrolled those already on it. In total, 469 participants were included in the analysis, with baseline apnoea-hypopnoea index values around 50 events per hour, indicating severe disease, and average body mass index near 39 kilograms per square metre.

The researchers retrospectively divided participants into four groups based on weight change at week 20: less than 5 percent, 5 to 10 percent, 10 to 15 percent, and 15 percent or more. The results revealed a clear dose-response relationship. In both trials, participants who achieved 15 percent or greater early weight reduction showed significantly greater reductions in the apnoea-hypopnoea index at both week 20 and week 52 compared with those losing less than 5 percent or 5 to 10 percent. The pattern held for percentage change in AHI as well, and across both trials, greater early weight loss correlated with greater AHI reduction at one year.

The remission data were the most eye-catching. By week 52, nearly half of trial 1 participants in the 10-to-15 percent early weight loss group had achieved OSA remission, defined as an AHI below 5 events per hour, or an AHI of 5 to 14 with minimal daytime sleepiness, and the remission rate reached 50.7 percent among those losing 15 percent or more. In trial 2, the picture was even more dramatic: 75.3 percent of participants with 15 percent or greater early weight loss achieved remission, with an odds ratio of 11.4 compared with the lowest weight loss group. By contrast, remission rates in the under-5 percent group languished between roughly 12 and 14 percent in both trials.

Beyond the breathing metrics, the analysis captured improvements in sleep apnoea-specific hypoxic burden, a measure of how much oxygen deprivation the body endures each hour. Participants in the highest weight loss category saw reductions of roughly 69 to 89 percent in this burden by week 52, far exceeding the improvements seen in lighter losers. Patient-reported outcomes told a parallel story, with significantly greater reductions in sleep disturbance and sleep-related impairment scores among the higher weight loss groups, alongside better physical component and general health scores on the SF-36 questionnaire.

The cardiometabolic ripple effects were equally notable. Participants achieving at least 10 percent early weight reduction showed improvements in systolic and diastolic blood pressure, high-density lipoprotein cholesterol, triglycerides, and inflammatory markers at follow-up, all of which are central to the cardiovascular risk that makes sleep apnoea so dangerous. Subgroup analyses suggested the benefits were consistent across age groups and disease severity, although participants with moderate apnoea showed meaningful improvement even with 5 to 10 percent early weight loss, while severe cases generally required the 10 percent or greater threshold.

Safety findings were reassuring across all weight loss categories, with no difference in serious adverse events between groups and no deaths related to adverse events. Gastrointestinal symptoms such as diarrhoea, nausea, and constipation were the most common side effects, consistent with the known profile of incretin-based therapies, and were generally mild to moderate in severity.

The authors caution that the analysis was not pre-specified, that grouping participants by observed weight loss introduces potential selection bias, and that the 52-week follow-up leaves longer-term durability uncertain. The trial population, drawn from 60 sites across nine countries, may also not fully represent the broader clinical population. Still, the implications are hard to ignore. If the magnitude of weight loss at week 20 proves to be a reliable prognostic marker, it could serve as a clinical decision point: patients responding robustly could be encouraged to continue intensive weight management, while those losing less than 5 percent might prompt timely escalation of therapy, whether through intensified lifestyle intervention, optimised pharmacotherapy, or initiation of positive airway pressure. In a field where treatment has often been reactive, the study suggests that the earliest months of weight loss may hold the key to rewriting the long-term course of one of the world’s most common chronic diseases.

Subject of Research: The relationship between early body weight reduction and long-term treatment outcomes in obstructive sleep apnoea with obesity

Article Title: Association between early body weight reduction and treatment outcomes in participants with obstructive sleep apnoea and obesity: a post hoc analysis of SURMOUNT-OSA trials

Article References: Lin, Y. N., Sun, X. W., Dai, S. J., Zhuang, H. X., Liu, J. J., & Li, Q. Y. (2026). Association between early body weight reduction and treatment outcomes in participants with obstructive sleep apnoea and obesity: a post hoc analysis of SURMOUNT-OSA trials. eClinicalMedicine, 100, Article 104203. https://doi.org/10.1016/j.eclinm.2026.104203

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104203

Keywords: obstructive sleep apnoea, obesity, weight loss, tirzepatide, SURMOUNT-OSA, apnoea-hypopnoea index, GLP-1 receptor agonist, hypoxic burden, cardiometabolic risk, sleep medicine, eClinicalMedicine, OSA remission